These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 24445513)

  • 1. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy.
    Mealy MA; Wingerchuk DM; Palace J; Greenberg BM; Levy M
    JAMA Neurol; 2014 Mar; 71(3):324-30. PubMed ID: 24445513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the treatment of neuromyelitis optica.
    Torres J; Pruitt A; Balcer L; Galetta S; Markowitz C; Dahodwala N
    J Neurol Sci; 2015 Apr; 351(1-2):31-35. PubMed ID: 25727350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Ma J; Yu H; Wang H; Zhang X; Feng K
    J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder.
    Chen H; Qiu W; Zhang Q; Wang J; Shi Z; Liu J; Lian Z; Feng H; Miao X; Zhou H
    Eur J Neurol; 2017 Jan; 24(1):219-226. PubMed ID: 27783452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients.
    Jacob A; Matiello M; Weinshenker BG; Wingerchuk DM; Lucchinetti C; Shuster E; Carter J; Keegan BM; Kantarci OH; Pittock SJ
    Arch Neurol; 2009 Sep; 66(9):1128-33. PubMed ID: 19752302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica.
    Costanzi C; Matiello M; Lucchinetti CF; Weinshenker BG; Pittock SJ; Mandrekar J; Thapa P; McKeon A
    Neurology; 2011 Aug; 77(7):659-66. PubMed ID: 21813788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.
    Kim SH; Huh SY; Lee SJ; Joung A; Kim HJ
    JAMA Neurol; 2013 Sep; 70(9):1110-7. PubMed ID: 23897062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints.
    Jeong IH; Park B; Kim SH; Hyun JW; Joo J; Kim HJ
    Mult Scler; 2016 Mar; 22(3):329-39. PubMed ID: 26041804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study.
    Zhang M; Zhang C; Bai P; Xue H; Wang G
    Acta Neurol Belg; 2017 Sep; 117(3):695-702. PubMed ID: 28608315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders.
    Kim SH; Hyun JW; Joung A; Park EY; Joo J; Kim HJ
    Mult Scler; 2017 Dec; 23(14):1902-1908. PubMed ID: 28080220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.
    Jacob A; Weinshenker BG; Violich I; McLinskey N; Krupp L; Fox RJ; Wingerchuk DM; Boggild M; Constantinescu CS; Miller A; De Angelis T; Matiello M; Cree BA
    Arch Neurol; 2008 Nov; 65(11):1443-8. PubMed ID: 18779415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.
    Velasco M; Zarco LA; Agudelo-Arrieta M; Torres-Camacho I; Garcia-Cifuentes E; Muñoz O
    Mult Scler Relat Disord; 2021 May; 50():102869. PubMed ID: 33711580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders.
    Mealy MA; Kim SH; Schmidt F; López R; Jimenez Arango JA; Paul F; Wingerchuk DM; Greenberg BM; Kim HJ; Levy M
    Mult Scler; 2018 Nov; 24(13):1737-1742. PubMed ID: 28857723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder.
    Huh SY; Kim SH; Hyun JW; Joung AR; Park MS; Kim BJ; Kim HJ
    JAMA Neurol; 2014 Nov; 71(11):1372-8. PubMed ID: 25199960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years.
    Kim SH; Kim W; Li XF; Jung IJ; Kim HJ
    Arch Neurol; 2011 Nov; 68(11):1412-20. PubMed ID: 21747007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
    Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG
    J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder.
    Ringelstein M; Ayzenberg I; Harmel J; Lauenstein AS; Lensch E; Stögbauer F; Hellwig K; Ellrichmann G; Stettner M; Chan A; Hartung HP; Kieseier B; Gold R; Aktas O; Kleiter I
    JAMA Neurol; 2015 Jul; 72(7):756-63. PubMed ID: 25985228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Efficacy and Tolerability of Mycophenolate Mofetil in Treating Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder in Western China.
    Chen H; Zhang Y; Shi Z; Feng H; Yao S; Xie J; Zhou H
    Clin Neuropharmacol; 2016; 39(2):81-7. PubMed ID: 26818042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of neuromyelitis optica: an evidence based review.
    Sato D; Callegaro D; Lana-Peixoto MA; Fujihara K;
    Arq Neuropsiquiatr; 2012 Jan; 70(1):59-66. PubMed ID: 22218475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical spectrum of CNS aquaporin-4 autoimmunity.
    Kim SH; Kim W; Li XF; Jung IJ; Kim HJ
    Neurology; 2012 Apr; 78(15):1179-85. PubMed ID: 22459676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.